首页> 外文会议>Proceedings of the American Thoracic Society;PATS >Chronic Lung Allograft Rejection Mechanisms and Therapy
【24h】

Chronic Lung Allograft Rejection Mechanisms and Therapy

机译:慢性同种异体移植排斥反应的机制和治疗

获取原文

摘要

Lung transplantation is a therapeutic option for patients with end-stage pulmonary disorders. Unfortunately, due to post-lung transplant complications, both infectious and noninfectious, it is only a treatment and not a cure. Importantly, despite induction combined with triple or quadruple maintenance immunosuppressive therapy, chronic lung rejection, in the form of obliterative bronchio-litis or its clinical correlate bronchiolitis obliterans syndrome (BOS), continues to be highly prevalent and is the major limitation to long-term survival. In this review we evaluate the presentation, diagnosis, histopathology, pathologic mechanisms, risk factors, and prevention/treatment options for BOS. A better understanding of the risk factors and how it relates to the pathologic mechanisms of chronic lung allograft rejection should lead to better pharmacologic targets to prevent/treat this syndrome without increasing the recipient's risk for infections.
机译:肺移植是晚期肺部疾病患者的治疗选择。不幸的是,由于肺部移植后的感染性和非感染性并发症,它只是一种治疗方法,而不是治愈方法。重要的是,尽管诱导疗法与三重或四重维持免疫抑制疗法相结合,但是以闭塞性支气管炎或其临床相关性闭塞性细支气管炎综合征(BOS)形式出现的慢性肺排斥仍然很普遍,并且是长期使用的主要限制生存。在这篇综述中,我们评估了BOS的表现,诊断,组织病理学,病理机制,危险因素以及预防/治疗选择。更好地了解危险因素及其与慢性同种异体移植排斥反应的病理机制之间的关系,应导致更好的药理学目标,以预防/治疗该综合征而不增加接受者的感染风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号